<DOC>
	<DOCNO>NCT00027846</DOCNO>
	<brief_summary>RATIONALE : Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Giving chemotherapy surgery may shrink tumor remove surgery . PURPOSE : Phase II trial determine effectiveness specialize radiation therapy either alone chemotherapy second surgery treat child undergone surgery localize ependymoma .</brief_summary>
	<brief_title>Observation Radiation Therapy and/or Chemotherapy Second Surgery Treating Children Who Have Undergone Surgery Ependymoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine local control pattern failure child completely resect , differentiate , supratentorial localize ependymoma initial surgical resection alone . - Determine rate complete resection second surgery chemotherapy patient initially incompletely resect localized ependymoma . - Determine local control pattern failure patient treat conformal radiotherapy . - Determine influence histologic grade time progression patient treatment conformal radiotherapy . OUTLINE : This multicenter study . Patients stratify accord extent prior surgical resection . - Group 1 ( patient supratentorial differentiate ependymoma undergone gross total resection visible residual tumor ) : Patients undergo observation . - Group 2 ( patient supratentorial anaplastic ependymoma infratentorial anaplastic differentiate ependymoma undergone gross total resection near total resection ) : Patients undergo conformal radiotherapy brain daily 5 day week 6-6Â½ week . - Group 3 ( patient tumor histology location undergone subtotal resection ) : Patients receive initial course chemotherapy comprise vincristine IV day 1 8 , carboplatin IV 1 hour day 1 , cyclophosphamide IV 1 hour day 1 2 . Patients also receive filgrastim ( G-CSF ) subcutaneously IV begin day 3 continue blood count recover . Patients receive second course chemotherapy comprise vincristine IV day 1 8 , carboplatin IV 1 hour day 1 , oral etoposide day 1-21 . After completion chemotherapy , patient evaluate second surgery . Patients unresectable disease undergo conformal radiotherapy . Patients resectable disease undergo second surgery follow conformal radiotherapy . Patients follow every 4 month 3 year , every 6 month 2 year , annually thereafter . PROJECTED ACCRUAL : A total 250-350 patient accrue study within 5 year .</detailed_description>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Ependymoma</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vincristine</mesh_term>
	<mesh_term>Podophyllotoxin</mesh_term>
	<mesh_term>Lenograstim</mesh_term>
	<mesh_term>Mesna</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm intracranial ependymoma Differentiated ependymoma anaplastic ependymoma No primary spinal cord ependymoma , myxopapillary ependymoma , subependymoma , ependymoblastoma , mixed glioma No evidence noncontiguous spread beyond primary site Initial surgical resection within past 56 day PATIENT CHARACTERISTICS : Age : 1 21 Performance status : No restriction Life expectancy : At least 2 month Hematopoietic : Not specify Hepatic : Not specify Renal : Not specify Other : Able undergo MRI Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception PRIOR CONCURRENT THERAPY : Biologic therapy : Not specify Chemotherapy : No prior chemotherapy Endocrine therapy : Prior concurrent corticosteroid allow Radiotherapy : No prior radiotherapy Surgery : See Disease Characteristics More 1 prior surgery allow Other : No prior treatment ependymoma</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>childhood supratentorial ependymoma</keyword>
	<keyword>newly diagnose childhood ependymoma</keyword>
	<keyword>childhood infratentorial ependymoma</keyword>
</DOC>